PTC Therapeutics shareholders back board, pay plan
PTC Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
PTC Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 2, 2026. As of the April 10, 2026 record date, 82,911,783 common shares were outstanding, with each share entitled to one vote.
Stockholders elected four Class I directors to serve until the 2029 annual meeting: Jessica Chutter, Matthew B. Klein, M.D., M.S., F.A.C.S., Stephanie S. Okey, M.S., and Jerome B. Zeldis, M.D., Ph.D., each receiving over 68.9 million votes “For.”
Ernst & Young LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026, with 76,170,292 votes “For.” A non-binding advisory vote on named executive officer compensation was also approved, receiving 71,166,204 votes “For.”
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding eligible to vote: 82,911,783 shares
Votes for Jessica Chutter: 71,945,515 votes
Votes for Matthew B. Klein: 71,550,878 votes
+4 more
7 metrics
Shares outstanding eligible to vote
82,911,783 shares
Common stock outstanding as of April 10, 2026 record date
Votes for Jessica Chutter
71,945,515 votes
Election as Class I director at 2026 annual meeting
Votes for Matthew B. Klein
71,550,878 votes
Election as Class I director at 2026 annual meeting
Votes for Stephanie S. Okey
68,902,707 votes
Election as Class I director at 2026 annual meeting
Votes for Jerome B. Zeldis
69,821,943 votes
Election as Class I director at 2026 annual meeting
Auditor ratification votes For
76,170,292 votes
Ernst & Young LLP ratified for year ending December 31, 2026
Executive pay advisory votes For
71,166,204 votes
Non-binding advisory proposal on named executive officer compensation
Key Terms
broker non-votes, non-binding advisory proposal, independent registered public accounting firm, Annual Meeting, +1 more
5 terms
broker non-votes financial
"The non-binding advisory proposal on named executive officer compensation was approved ... and 3,858,311 broker non-votes."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding advisory proposal financial
"The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders..."
A non-binding advisory proposal is a shareholder vote that expresses investors’ opinions or recommendations to a company's board or management but does not have legal force to change policy. Think of it like a public poll or suggestion box: the result signals investor sentiment and can pressure leadership to act, influence reputation, or guide future binding decisions, so investors watch these votes for clues about governance and strategy.
independent registered public accounting firm financial
"The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified..."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Annual Meeting financial
"The Company held its Annual Meeting on June 2, 2026 (the “Annual Meeting”)."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
record date financial
"As of the record date of the Annual Meeting, April 10, 2026, there were 82,911,783 shares..."
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the main outcome of PTC Therapeutics (PTCT) 2026 annual meeting?
Stockholders elected four Class I directors and approved key proposals. Directors will serve until the 2029 annual meeting, and all management-backed items, including auditor ratification and executive pay, received strong support in the voting results.
Which directors were elected at PTC Therapeutics (PTCT) 2026 annual meeting?
Stockholders elected Jessica Chutter, Matthew B. Klein, M.D., M.S., F.A.C.S., Stephanie S. Okey, M.S., and Jerome B. Zeldis, M.D., Ph.D. Each was elected as a Class I director to serve until the company’s 2029 annual meeting of stockholders.
Did PTC Therapeutics (PTCT) stockholders approve the company’s auditor for 2026?
Yes, stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The ratification received 76,170,292 votes “For,” 355,794 “Against,” and 15,520 “Abstained.”
How did PTC Therapeutics (PTCT) stockholders vote on executive compensation?
Stockholders approved the non-binding advisory proposal on named executive officer compensation. The vote totaled 71,166,204 “For,” 1,492,801 “Against,” 24,290 “Abstained,” and 3,858,311 broker non-votes, indicating majority support for the compensation program.
What are broker non-votes in PTC Therapeutics (PTCT) 2026 voting results?
Broker non-votes are shares held in street name where brokers did not receive specific voting instructions for certain items. For several proposals, the results disclose 3,858,311 broker non-votes, reflecting uninstructed shares not counted as “For” or “Against.”
AI-generated analysis. How Rhea-AI works. Not financial advice.
